Bioorganic & Medicinal Chemistry Letters 21 (2011) 6328–6331

Contents lists available at SciVerse ScienceDirect

Bioorganic & Medicinal Chemistry Letters

journal homepage: www.elsevier.com/locate/bmcl

Antiviral activity of novel 2′-fluoro-6′-methylene-carbocyclic adenosine against wild-type and drug-resistant hepatitis B virus mutants

Jianing Wang [a], Uma S. Singh [a], Ravindra K. Rawal [a], Massaya Sugiyama [b], Jakyung Yoo [a], Ashok K. Jha [a], Melissa Scroggin [a], Zhuhui Huang [c], Michael G. Murray [c], Rajgopal Govindarajan [a], Yasuhito Tanaka [b], Brent Korba [d], Chung K. Chu [a,*]

[a] The University of Georgia, College of Pharmacy, Athens, GA 30602, USA
[b] Nagoya City University, Graduate School of Medical Sciences, Nagoya 467-8601, Japan
[c] Southern Research Institute, Frederick, MD 21701, USA
[d] Georgetown University Medical Center, Washington, DC 20057, USA

ARTICLE INFO

Article history:
Received 29 June 2011
Revised 25 August 2011
Accepted 26 August 2011
Available online 1 September 2011

Keywords:
Carbocyclic nucleoside
anti-HBV
Drug-resistant

ABSTRACT

Novel 2′-fluoro-6′-methylene-carbocyclic adenosine (**9**) was synthesized and evaluated its anti-HBV activity. The titled compound demonstrated significant antiviral activity against wild-type as well as lamivudine, adefovir and double lamivudine/entecavir resistant mutants. Molecular modeling study indicate that the 2′-fluoro moiety by a hydrogen bond, as well as the van der Waals interaction of the carbocyclic ring with the phenylalanine moiety of the polymerase promote the positive binding, even in the drug resistant mutants.

Published by Elsevier Ltd.

Chronic hepatitis B virus (HBV) infection is one of the leading causes of morbidity and mortality worldwide. Chronic infection with HBV occurs in approximately 350 million of the world population, including 1.7 million in the USA.[1] HBV infection can persist for the life of the host, often leading to severe consequences such as liver failure, cirrhosis and eventually hepatocellular carcinoma, resulting in annually 0.5–1.2 million deaths worldwide.[2] HBV is an incomplete double-stranded DNA virus. Its DNA replication is unique because it includes a reverse transcription step. The HBV DNA polymerase/reverse transcriptase is an essential and multifunctional enzyme, which operates as a DNA polymerase/reverse transcriptase, an RNAse H, through coordinating the assembly of viral nucleocapsids, as well as catalyzing the generation of DNA primers.[3] Nucleoside analogues can suppress HBV replication by inhibiting the viral polymerase/reverse transcriptase. The pivotal role of nucleoside/nucleotide analogues such as lamivudine, adefovir, telbivudine, entecavir, clevudine, and tenofovir has been demonstrated by their therapeutic efficacy in clinical practice. However, long-term therapy with these drugs is often associated with viral resistance, which significantly compromises the clinical application of these agents. For example, the extensive use of lamivudine resulted in the emergence of mutants that are resistant to the anti-HBV activity; 24% after a 1-year therapy, increasing to over 70% after 4 years of therapy. Adefovir has been used for the patients, who develop lamivudine-resistant mutants, however, a significant number of patients (29% after 5 years of use) also develop the adefovir resistant mutant (N236T).

Entecavir is a carbocyclic 2′-deoxyguanosine analog that demonstrates potent anti-HBV activity[4] and is recommended for patients with the wild-type strain as well as for those patients harboring lamivudine-resistant strains.[5] However, a recent study by Tanaka and his co-workers suggest that the viral breakthrough was observed in the lamivudine-refractory group in 4.9% of patients at baseline and increase to 14.6%, 24% and 44.8% at weeks 48, 96 and 144, respectively.[6]

In view of the fact that currently adefovir and entecavir are the most prescribed drugs for the treatment of chronic HBV infection, it is critical to discover the agents that do not confer cross-resistance with the adefovir and lamivudine/entecavir-mutants for the future treatment of drug resistant patients. In this report we try to demonstrate that our newly discovered compound **9** may potentially play a significant role for that purpose.

Carbocyclic nucleosides are an interesting class of compounds in which the methylene group replaces the oxygen atom of a furanose ring. As a consequence, the glycosidic bond is resistant to nucleoside phosphorylase as well as nucleoside hydrolase, which makes the carbocyclic nucleosides more stable towards metabolic

* Corresponding author. Address: Department of Pharmaceutical and Biomedical Sciences, College of Pharmacy, The University of Georgia, Athens, GA 30602, USA. Tel.: +1 706 542 5379; fax: +1 706 542 5381.
E-mail addresses: DCHU@rx.uga.edu, DCHU@mail.rx.uga.edu (C.K. Chu).

0960-894X/$ - see front matter Published by Elsevier Ltd.
doi:10.1016/j.bmcl.2011.08.113



Scheme 1. Synthesis of target compound **9**. Reagents and conditions: (a) NaH, BnBr, DMF, 0 °C; (b) TFA/H_2O (2:1), 50 °C; (c) $TIDPSCl_2$/imidazole, DMF, 0 °C; (d) DAST, CH_2Cl_2, rt; (e) TBAF/AcOH, THF, rt; (f) BzCl, pyridine, rt; (g) BCl_3, CH_2Cl_2, −78 °C; (h) *N*,*N*-dibocprotected adenine, DIAD, Ph_3P, THF, 0 °C; (i) TFA, CH_2Cl_2, rt; (j) DIBAL-H, CH_2Cl_2, −78 °C.

degradation.[7] Due to these features, carbocyclic nucleosides have received much attention as potential chemotherapeutic agents.[8] Carbovir and entecavir are examples of results of these efforts.

It is also well known that incorporation of a fluorine atom at the 2′-position of nucleosides can increase the stability of the glycosyl bond towards chemical and metabolic degradation.[9,10] A fluorine substitution on the carbocyclic sugar moiety has been proven to be useful in producing effective antiviral agents as demonstrated by our group in 2′-fluoro-5-methyl-β-L-arabinofuranosyluracil (L-FMAU or clevudine)[11] as well as in clofarabine.[12]

In view of the 2′-F substitution[9,10] as well the introduction of an exocyclic double bond to carbocyclic nucleosides,[4] which have been beneficial for anti-HBV activity such as in entecavir, 2′-fluoro-6′-methylene-carbocyclic adenosine or (+)-9-[(1*R*,2*R*,3*R*,4*R*)-2-fluoro-3-hydroxy-4-(hydroxymethyl)-5-methylenecyclopentan-1-yl] adenine **9** was synthesized and evaluated for its antiviral activity against wild-type HBV as well as adefovir, lamivudine and lamivudine/entecavir (double)-resistant mutants in vitro.

The synthesis of the target nucleoside **9** commenced with compound **7** as the key intermediate (Scheme 1). Compound **1** was synthesized according to the reported procedure from our group.[13] The allylic hydroxyl group of **1** was protected with a benzyl group and subsequent deprotection of the acetonide and the *t*-butyl group of compound **2** gave **3** in 86% yield. The 3, 5-hydroxy groups of **3** were selectively protected with 1,3-dichloro-1,1,2,2-tetraisopropyl disilazine to give **4** in 95% yield. Transformation of the 2-β-hydroxyl group to 2-α-fluoro was accomplished by treating the alcohol **4** with DAST to give 47% yield of compound **5**. However, debenzylation of **5** was unsuccessful under the Birch reduction or the Lewis acid (BCl_3) conditions. Therefore, the silyl group of **5** was removed by using tetrabutyl ammonium fluoride (TBAF/HOAc) to yield 82% of a diol, which was re-protected by benzoyl chloride in pyridine to give the fully protected intermediate **6** in 86% yield. The compound **6** was then treated with BCl_3 at −78 °C to obtain the key intermediate **7** in 76% yield. *N*,*N*-diboc protected adenine was synthesized according to the reported protocol in literature[14] and condensed with **7** to obtain **8** in 51% yield. The deprotection of the Boc group was carried out by TFA to afford 82% yield. Eventually, the treatment of DIBAL-H gave the target compound **9**[15] in 76% yield.

The synthesized nucleoside **9** was evaluated for its antiviral activity against wild-type HBV as well as adefovir, lamivudine and lamivudine/entecavir-drug resistant mutants in vitro,[16] and the results are summarized in Table 1. As the compound **9** is a derivative of an adenine analog, we directly compared its antiviral activity to that of adefovir instead of entecavir (a guanine analog) although the carbocyclic moiety is similar to that of entecavir. Furthermore, compound **9**, an adenine analogue, can interact with the thymidine moiety in the DNA template–primer site while entecavir interacts with the cytosine moiety at the same site in the active site. Thus, the base moiety is the major deciding factor, not the sugar moiety in determining the mode of action.

The target compound **9** demonstrated a significant antiviral in vitro activity against wild-type (WT) HBV with an EC_{50} value of 1.5 μM. The antiviral potency was similar to that of adefovir, while being 7-fold less potent than lamivudine. However, the concentration of the compound **9** required to inhibit 90% (EC_{90}) of wild-type HBV is 4.5 μM, which is 1.5-fold more potent than adefovir (EC_{50} 7.1 μM; Table 1).

The compound **9** also showed excellent activity against both lamivudine and adefovir resistant HBV mutants.[17] Particularly, the compound **9** showed a 4.5-fold enhanced potency of EC_{50} (1.7 μM) and a 7.8-fold more favorable EC_{90} (4.6 μM) against adefovir mutant rtN236T. For lamivudine mutants, rtM204V and rtM204I, the compound **9** showed an EC_{50} value of 1.8 versus 1.6 μM for adefovir, and 1.0 versus 1.9 μM for compound **9** and adefovir, respectively, while in the EC_{90} value, compound **9** demonstrated more favorable anti-HBV activity for both mutants, rtM204 V (4.7 vs 7.0 μM) and rtM204I (5.0 vs 8.0 μM). For mutant rtL180M, the antiviral activity of compound **9** was similar to that of lamivudine in the EC_{50} 2.1 versus 1.5 μM, while the compound **9** exhibited a 4.3-fold increased antiviral activity in the EC_{90} value (5.1 vs 22.0 μM).

Compound **9** was also evaluated against the lamivudine double mutant, rtL180M/rtM204V, and it exhibited the EC_{50} 2.2 μM that was equal to the adefovir, while the EC_{90} value of 5.5 μM of compound **9** was more effective than that of adefovir (8.5 μM). In addition, deamination studies with adenosine deaminase from calf thymus indicated that the compound **9** was completely stable.[18]

In preliminary studies, compound **9** was also evaluated against lamivudine/entecavir double resistant clone (L180M + S202I + M202V), in which compound **9** demonstrated significant anti-HBV activity (EC_{50} 0.67 μM) against the mutant. In the case of lamivudine and entecavir, there are significant decrease in their